Jimu Biotechnology

Jimu Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development and commercialization of innovative ophthalmic therapies. Founded in 2019 and backed by prominent investors like 8VC, the company addresses significant unmet medical needs in eye care through a combination of novel drugs and advanced delivery systems. Their pipeline includes late-stage candidates for uveitic macular edema, myopia, and presbyopia, primarily licensed from international partners such as Clearside Biomedical and Eyenovia. Jimu's lead product, ARVN001, utilizes a proprietary suprachoroidal space microinjector to deliver triamcinolone acetonide directly to the back of the eye. By integrating specialized medical devices with pharmaceutical agents, Jimu aims to provide more effective and safer treatment options for patients across the Greater China region.